Physician profile
Anthony Lin
NPI 1316946254
$5,734.42
in general payments reported to CMS, 2019-2025
26 companies · $1,364 in 2025
The $1,364 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $725 · 2020: $227 · 2021: $197 · 2022: $728 · 2023: $963 · 2024: $1,530 · 2025: $1,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,826 · Education: $31.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,825.95 |
| Education | $31.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,421.27 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $724.55 | 2019-2025 | Xifaxan, Plenvu |
| Celgene Corporation | $587.35 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $557.24 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $478.14 | 2019-2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $459.98 | 2024-2025 | Voquezna |
| Pfizer INC. | $339.90 | 2019-2025 | |
| Genzyme Corporation | $196.71 | 2022-2025 | |
| Ardelyx, INC. | $178.81 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $131.03 | 2023-2025 | Dupixent |
| Madrigal Pharmaceuticals | $114.40 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $80.75 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $77.30 | 2020-2025 | |
| Qol Medical, LLC | $65.62 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $65.28 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $31.48 | 2024 | Zymfentra |
| Ipsen Biopharmaceuticals, INC | $28.26 | 2024 | Bylvay |
| Novo Nordisk INC | $26.55 | 2025 | Wegovy |
| Organon LLC | $25.54 | 2024 | |
| Braintree Laboratories, INC. | $24.73 | 2024 | Suflave, Sutab |
| Lucid Diagnostics INC. | $23.90 | 2025 | |
| Boston Scientific Corporation | $23.34 | 2019 | |
| Daiichi Sankyo INC. | $22.78 | 2019 | |
| Shire North American Group INC | $17.57 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.44 | 2023 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $15.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.